Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Axitinib,AX2023-US-001,2023,USA,MDV,350,62,32,68,27.5,45,85,12,15,30,40,15,55,25,15,5,20,35,30,18,7,3,9,4,8,25,35,Gemcitabine + Cisplatin,Paclitaxel + Carboplatin,5-FU + Leucovorin,Capecitabine,0,0,0,30,40,50,15,45,40,60,2
Axitinib,AX2022-EU-002,2022,Germany,Claim Database,420,68,28,72,26.8,52,78,15,12,28,45,15,60,20,15,5,18,32,35,22,9,4,11,5,10,30,40,Docetaxel + Cisplatin,Pemetrexed + Carboplatin,FOLFOX,CapeOX,0,0,0,35,45,55,20,50,30,70,3
Axitinib,AX2024-JP-003,2024,Japan,MDV,280,70,35,65,25.5,38,90,10,18,32,35,15,50,30,15,5,22,38,25,15,6,2,8,3,7,20,30,S-1 + Cisplatin,Docetaxel + S-1,UFT,Capecitabine + Oxaliplatin,0,0,0,25,35,45,25,40,35,55,2.5
